Insecticides India Q4 FY26: Growth Continues, But Margins and Working Capital Stay in Focus

Insecticides (India) Limited closed FY26 with steady top-line expansion, but the quarter-to-quarter picture was uneven. On a consolidated basis, revenue from operations rose to INR 2,140 crore in FY26 from INR 2,000 crore in FY25, a 7% increase. EBITDA increased modestly to INR 227 crore from INR 221 crore, while profit after tax softened to INR 139 crore from INR 142 crore.

The Q4 performance showed stronger revenue momentum but weaker profitability. Q4FY26 revenue grew 19% year on year to INR 426 crore. However, gross margin fell to 30.2% from 36.6% in Q4FY25, and EBITDA margin declined to 6.0% from 7.9%. PAT for the quarter came in at INR 12 crore versus INR 14 crore last year.

The management commentary linked FY26’s performance to disciplined execution in a mixed demand environment. It noted May demand softness due to rising heat and delayed buying ahead of monsoons, but indicated that activity typically improves as monsoon reaches the coastline in June.

Business mix: B2C remains the core, with herbicides a large and growing category

IIL’s sales mix continues to be anchored in domestic B2C. FY26 segment split was disclosed as 73% B2C, 22% B2B, and 5% exports. Within B2C, the company highlighted the category-wise revenue breakup for FY26: insecticides contributed 49%, herbicides 37%, fungicides 10%, and biologicals and PGR 4%.

Management commentary reinforced the structural trend of rising herbicide adoption, citing higher labour costs and the cost advantage of chemical weed control. It also acknowledged that herbicides faced channel pressure in the previous year due to adverse weather, goods returns, and pricing competition from newer off-patent launches.

Premiumization and new products: mix improvement continues

Premiumization remains a central theme in the investor presentation and the earnings call. In the deck, IIL reported that premium products as a share of B2C increased from 51% in FY23 to 58% in FY26. Management also described its internal premium classifications (Maharatna and Focus Maharatna) and stated that these contribute around 60% to 63% currently, with a stated ambition to reach 60% to 70% over the next 3 to 4 years.

The company reiterated that innovation-led launches and international partnerships are key enablers. It cited multiple collaborations, including with Nissan Chemical Corporation and Corteva Agriscience. On the call, management stated that products launched through the Corteva collaboration include SPARCLE and Granuvia, and it is about to launch two more products, SPINOACE and Green Mix.

The CFO also shared specific revenue datapoints from the call, including FY26 turnover of INR 322 crore from patented products, INR 324 crore from combination products, and INR 226 crore from in-licensing products. He also stated that five products launched during the year contributed INR 40 crore.

Working capital and finance cost: improvement in inventory days, but receivables increased

Working capital remains a key area to track. IIL’s net working capital days were 168 in FY26, marginally improved from 172 in FY25. Inventory reduced, with inventory days improving to 194 from 238. However, trade receivable days increased to 83 from 70, and trade payable days reduced to 109 from 136.

Management explained its channel approach in detail. It stated that the company does not leave unsold inventory with distributors at the end of a season and picks up leftover stock, attempting to redeploy it geographically or reformulate and reintroduce it if needed. While this can support channel health and collections, it can keep balance sheet inventory elevated.

The financial impact was visible in financing costs. Consolidated finance cost rose sharply to INR 16.88 crore in FY26 from INR 6.86 crore in FY25. Management linked the increase to higher inventory levels, greater utilization of bank limits, and investments in new products. It also mentioned an internal objective to reduce interest costs by 25% to 30%.

Capacity, capex, and Kaeros: parallel distribution as a strategic lever

On manufacturing readiness, the deck highlighted multiple facilities and capacity, including 15,800 MTPA of active ingredient and intermediates, and formulation capacities across granules, liquids and powders. Management stated that facilities at Dahej and the upcoming Sotanala plant provide capacity headroom for future growth.

Importantly, management guided that future capex is expected to be largely maintenance once ongoing projects are completed in FY27, indicating a likely range of INR 25 to 30 crore for maintenance capex.

A key strategic initiative discussed in both the presentation and the call is Kaeros, the fully owned subsidiary aimed at building an incremental dealer ecosystem and strengthening distribution depth. On the call, management described Kaeros as a platform with three objectives: building a parallel distribution network, enabling direct imports of technicals from China, and scaling B2B pack-to-pack activities once regulatory permissions and network coverage are in place. Management stated there would be no common distributor between IIL and Kaeros.

Takeaways

FY26 reflects a company that is growing steadily but still navigating the operational realities of a seasonal, channel-driven business. IIL’s disclosures show stable revenue growth, an improving premium mix over a multi-year period, and a clear strategy around partnerships, new launches and distribution depth.

At the same time, Q4 margin compression, elevated working capital, and a sharp rise in finance costs remain areas investors will watch closely in FY27. Management’s own commentary indicates that the near-term outcome will be influenced by monsoon timing, demand recovery through June, and the ability to convert inventory positioning and pricing actions into improved margins and cash flows.